GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (MEX:WST) » Definitions » Other Operating Expense

West Pharmaceutical Services (MEX:WST) Other Operating Expense : MXN-0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is West Pharmaceutical Services Other Operating Expense?

West Pharmaceutical Services's Other Operating Expense for the three months ended in Mar. 2025 was MXN-0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was MXN-0 Mil.

West Pharmaceutical Services's quarterly Other Operating Expense increased from Sep. 2024 (MXN-0 Mil) to Dec. 2024 (MXN0 Mil) but then declined from Dec. 2024 (MXN0 Mil) to Mar. 2025 (MXN-0 Mil).

West Pharmaceutical Services's annual Other Operating Expense increased from Dec. 2022 (MXN-0 Mil) to Dec. 2023 (MXN0 Mil) and increased from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil).


West Pharmaceutical Services Other Operating Expense Historical Data

The historical data trend for West Pharmaceutical Services's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Other Operating Expense Chart

West Pharmaceutical Services Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

West Pharmaceutical Services Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

West Pharmaceutical Services Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


West Pharmaceutical Services Other Operating Expense Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


West Pharmaceutical Services Business Description

Traded in Other Exchanges
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.